Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells $27,300.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Kinney Horn sold 1,092 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $25.00, for a total transaction of $27,300.00. Following the transaction, the insider owned 1,092 shares in the company, valued at $27,300. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 0.6%

Shares of IMNM traded up $0.15 during midday trading on Thursday, hitting $24.16. The company had a trading volume of 1,207,061 shares, compared to its average volume of 1,442,420. The company’s 50 day moving average price is $21.00 and its 200 day moving average price is $21.86. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -10.15 and a beta of 2.07. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. Equities analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IMNM shares. Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Finally, Leerink Partners decreased their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. boosted its position in Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. lifted its stake in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA lifted its stake in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Immunome in the fourth quarter valued at $30,710,000. Finally, Sofinnova Investments Inc. boosted its holdings in shares of Immunome by 271.2% during the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after acquiring an additional 1,182,426 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.